A $2.6 billion deal united contract manufacturers Patheon and DSM Pharmaceutical Products, and now the combined company has emerged to do business under the monicker DPx, expecting to bank $2 billion in revenue this year. Private equity outfit JLL Partners controls 51% of DPx, with Royal DSM holding onto the rest, and the new company boasts 24 locations across North America, Europe, Latin America and Australia, and more than 8,000 employees. More